Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries.

Campbell JR, Johnston JC, Cook VJ, Sadatsafavi M, Elwood RK, Marra F.

Emerg Infect Dis. 2019 Apr;25(4):661-671. doi: 10.3201/eid2504.171630.

2.

Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada.

Campbell JR, Johnston JC, Sadatsafavi M, Cook VJ, Elwood RK, Marra F.

PLoS One. 2017 Oct 30;12(10):e0186778. doi: 10.1371/journal.pone.0186778. eCollection 2017.

3.

Patient preference for latent tuberculosis infection preventive treatment: a discrete choice experiment.

Guo N, Marra CA, FitzGerald JM, Elwood RK, Anis AH, Marra F.

Value Health. 2011 Sep-Oct;14(6):937-43. doi: 10.1016/j.jval.2011.05.003. Epub 2011 Jul 29.

4.

Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic?

Wang M, Fitzgerald JM, Richardson K, Marra CA, Cook VJ, Hajek J, Elwood RK, Bowie WR, Marra F.

Int J Tuberc Lung Dis. 2011 Aug;15(8):1062-8. doi: 10.5588/ijtld.10.0734.

PMID:
21740669
5.

Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis.

Guo N, Marra F, Fitzgerald JM, Elwood RK, Marra CA.

Eur Respir J. 2010 Jul;36(1):206-8. doi: 10.1183/09031936.00159409. No abstract available.

6.

Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008.

Hernández-Garduño E, Elwood RK.

Emerg Infect Dis. 2010 Jun;16(6):1047; author reply 1047-8. doi: 10.3201/eid1606.100228. No abstract available.

7.

Demographic risk factors of pulmonary colonization by non-tuberculous mycobacteria.

Hernández-Garduño E, Elwood RK.

Int J Tuberc Lung Dis. 2010 Jan;14(1):106-12.

PMID:
20003703
8.

Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.

Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, Fitzgerald JM, Elwood RK, Brooks-Wilson A, Marra F.

Pharmacogenomics. 2009 Sep;10(9):1433-45. doi: 10.2217/pgs.09.66. Erratum in: Pharmacogenomics. 2010 Sep;11(9):1343.

PMID:
19761367
9.

The incidence of pulmonary non-tuberculous mycobacteria in British Columbia, Canada.

Hernández-Garduño E, Rodrigues M, Elwood RK.

Int J Tuberc Lung Dis. 2009 Sep;13(9):1086-93.

PMID:
19723396
10.

Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts.

Marra F, Marra CA, Sadatsafavi M, Morán-Mendoza O, Cook V, Elwood RK, Morshed M, Brunham RC, Fitzgerald JM.

Int J Tuberc Lung Dis. 2008 Dec;12(12):1414-24.

PMID:
19017451
11.

Risk of tuberculosis in screened subjects without known risk factors for active disease.

Cook VJ, Hernández-Garduño E, Elwood RK.

Int J Tuberc Lung Dis. 2008 Aug;12(8):903-8.

PMID:
18647449
12.
13.

Cost-effectiveness of LTBI treatment for TB contacts in British Columbia.

Tan MC, Marra CA, Sadatsafavi M, Marra F, Morán-Mendoza O, Moadebi S, Elwood RK, FitzGerald JM.

Value Health. 2008 Sep-Oct;11(5):842-52. doi: 10.1111/j.1524-4733.2008.00334.x. Epub 2008 Jul 15.

14.

Health state utilities in latent and active tuberculosis.

Guo N, Marra CA, Marra F, Moadebi S, Elwood RK, Fitzgerald JM.

Value Health. 2008 Dec;11(7):1154-61. doi: 10.1111/j.1524-4733.2008.00355.x. Epub 2008 May 16.

15.

Health-related quality of life trajectories among adults with tuberculosis: differences between latent and active infection.

Marra CA, Marra F, Colley L, Moadebi S, Elwood RK, Fitzgerald JM.

Chest. 2008 Feb;133(2):396-403. doi: 10.1378/chest.07-1494. Epub 2008 Jan 15.

PMID:
18198260
16.

Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.

Marra F, Marra CA, Bruchet N, Richardson K, Moadebi S, Elwood RK, Fitzgerald JM.

Int J Tuberc Lung Dis. 2007 Aug;11(8):868-75.

PMID:
17705952
17.

BCG vaccination and the prevalence of latent tuberculosis infection in an aboriginal population.

Cook VJ, Kuramoto L, Noertjojo K, Elwood RK, Fitzgerald JM.

Int J Tuberc Lung Dis. 2006 Dec;10(12):1347-53.

PMID:
17167951
18.
19.

Impact of country of origin on drug-resistant tuberculosis among foreign-born persons in British Columbia.

Moniruzzaman A, Elwood RK, Schulzer M, FitzGerald JM.

Int J Tuberc Lung Dis. 2006 Aug;10(8):844-50.

PMID:
16898367
20.

A population-based study of risk factors for drug-resistant TB in British Columbia.

Moniruzzaman A, Elwood RK, Schulzer M, FitzGerald JM.

Int J Tuberc Lung Dis. 2006 Jun;10(6):631-8.

PMID:
16776450
21.

Levofloxacin treatment of active tuberculosis and the risk of adverse events.

Marra F, Marra CA, Moadebi S, Shi P, Elwood RK, Stark G, FitzGerald JM.

Chest. 2005 Sep;128(3):1406-13.

PMID:
16162736
22.

Primary immune deficiencies presenting in adults: seven years of experience from Iran.

Mansouri D, Adimi P, Mirsaedi M, Mansouri N, Tabarsi P, Amiri M, Jamaati HR, Motavasseli M, Baghaii N, Cheraghvandi A, Rouhi R, Roozbahany NA, Zahirifard S, Mohammadi F, Masjedi MR, Velayati AA, Casanova JL, Speert DP, Elwood RK, Schellenberg R, Turvey SE.

J Clin Immunol. 2005 Jul;25(4):385-91.

PMID:
16133995
23.

The lack of association between bacille Calmette-Guerin vaccination and clustering of Aboriginals with tuberculosis in western Canada.

Cook VJ, Hernández-Garduño E, Kunimoto D, Hershfield ES, Fanning EA, Hoeppner VH, Elwood RK, FitzGerald JM; Canadian Molecular Epidemiology of Tuberculosis Study Group.

Can Respir J. 2005 Apr;12(3):134-8.

24.

Risk of tuberculosis in children from smear-negative source cases.

Elwood RK, Cook VJ, Hernández-Garduño E.

Int J Tuberc Lung Dis. 2005 Jan;9(1):49-55.

PMID:
15675550
25.

Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant.

Marra F, Cox VC, FitzGerald JM, Moadebi S, Elwood RK.

Int J Tuberc Lung Dis. 2004 Jul;8(7):905-9.

PMID:
15260286
26.

Transmission of tuberculosis from smear negative patients: a molecular epidemiology study.

Hernández-Garduño E, Cook V, Kunimoto D, Elwood RK, Black WA, FitzGerald JM.

Thorax. 2004 Apr;59(4):286-90.

27.

Incidence of pulmonary disease caused by mycobacteria other than tuberculosis in British Columbia.

Elwood RK, Opazo Saez AM, Lentini V, Shadmani R.

Can Respir J. 2002 Sep-Oct;9(5):319-23.

28.

A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements.

Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM.

Thorax. 2002 Sep;57(9):804-9. Erratum in: Thorax. 2003 Feb;58(2):188..

29.

Predictors of clustering of tuberculosis in Greater Vancouver: a molecular epidemiologic study.

Hernández-Garduño E, Kunimoto D, Wang L, Rodrigues M, Elwood RK, Black W, Mak S, FitzGerald JM.

CMAJ. 2002 Aug 20;167(4):349-52.

30.

Tuberculosis among aboriginal and nonaboriginal persons in British Columbia.

Wang L, Noertjojo K, Elwood RK, FitzGerald JM.

Can Respir J. 2000 Mar-Apr;7(2):151-7.

31.

Tuberculosis: 13. Control of the disease among aboriginal people in Canada.

FitzGerald JM, Wang L, Elwood RK.

CMAJ. 2000 Feb 8;162(3):351-5. Review. No abstract available.

32.

Dialysis patients with tuberculosis.

FitzGerald JM, Elwood RK, Chia S.

CMAJ. 1999 Sep 7;161(5):489. No abstract available.

33.

The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis.

Al-Moamary MS, Black W, Bessuille E, Elwood RK, Vedal S.

Chest. 1999 Sep;116(3):726-31.

PMID:
10492279
34.

Use of incentives to increase compliance for TB screening in a population of intravenous drug users. Vancouver Injection Drug Use Study Group.

FitzGerald JM, Patrick DM, Strathdee S, Rekart M, Elwood RK, Schecter MT, Montaner J, O'Shaughnessy M.

Int J Tuberc Lung Dis. 1999 Feb;3(2):153-5.

PMID:
10091882
35.

Severe hepatic complications of antituberculous therapy.

Turner MO, Elwood RK.

Can J Infect Dis. 1999 Mar;10(2):167-9.

36.

Risk of tuberculosis in dialysis patients: a population-based study.

Chia S, Karim M, Elwood RK, FitzGerald JM.

Int J Tuberc Lung Dis. 1998 Dec;2(12):989-91.

PMID:
9869114
37.
38.

Tuberculosis screening for immigrants and refugees: diagnostic outcomes in the state of Hawaii.

Turner MO, Elwood RK.

Am J Respir Crit Care Med. 1997 Feb;155(2):771. No abstract available.

PMID:
9032229
39.

HIV-related tuberculosis in British Columbia: indications of a rise in prevalence and a change in risk groups.

Blenkush MF, Korzeniewska-Kozela M, Elwood RK, Black W, FitzGerald JM.

Clin Invest Med. 1996 Aug;19(4):271-8.

PMID:
8853575
40.

Evidence for TB clustering in Vancouver: results from pilot study using RFLP fingerprinting.

Blenkush M, Kunimoto D, Black W, Elwood RK, FitzGerald JM.

Can Commun Dis Rep. 1996 Apr 1;22(7):49-51. English, French. No abstract available.

41.

Alopecia side-effect of antituberculosis drugs.

FitzGerald JM, Turner MT, Dean S, Elwood RK.

Lancet. 1996 Feb 17;347(8999):472. No abstract available.

PMID:
8618506
42.

Interpreting tuberculin skin tests.

Elwood RK.

Can Fam Physician. 1995 Oct;41:1665-6. No abstract available.

43.

Soft tissue tuberculosis: a series of 11 cases.

Puttick MP, Stein HB, Chan RM, Elwood RK, How AR, Reid GD.

J Rheumatol. 1995 Jul;22(7):1321-5. Review.

PMID:
7562766
44.

Long-Term Home Oxygen Therapy: A rational approach.

Elwood RK.

Can Fam Physician. 1992 Apr;38:901-44.

45.

Tuberculosis of the ribs--a report of three cases.

Wiebe ER, Elwood RK.

Respir Med. 1991 May;85(3):251-3. No abstract available.

PMID:
1909046
46.

Abdominal tuberculosis: a critical review.

Fitzgerald JM, Menzies RI, Elwood RK.

Dig Dis. 1991;9(5):269-81. Review. No abstract available.

PMID:
1752066
47.

Clinical features of abdominal tuberculosis.

Jakubowski A, Elwood RK, Enarson DA.

J Infect Dis. 1988 Oct;158(4):687-92.

PMID:
3171223
48.

Active abdominal tuberculosis in Canada in 1970-81.

Jakubowski A, Elwood RK, Enarson DA.

CMAJ. 1987 Nov 15;137(10):897-900.

49.

Ocular toxicity following ethambutol in standard dosage.

Elwood RK.

Br J Dis Chest. 1987 Apr;81(2):207. No abstract available.

PMID:
3651315
50.

Increased airway mucosal permeability of smokers. Relationship to airway reactivity.

Kennedy SM, Elwood RK, Wiggs BJ, Paré PD, Hogg JC.

Am Rev Respir Dis. 1984 Jan;129(1):143-8.

PMID:
6142669

Supplemental Content

Loading ...
Support Center